Company / Cost of Revenue
IRADIMED CORP Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$19.5M
FY2025
5-year range
$8.8M / $19.5M
FY2021-FY2025
Trend
+15.4%
vs FY2024
Sector context
#110 of 113
Health Care
What the data says
Among 113 Health Care companies, IRADIMED CORP is in the top 3% for cost of revenue. Cost of Revenue has increased for 5 consecutive years, from $8M in FY2020 to $19M in FY2025.
Based on SEC 10-K filings.
$19M in FY2025 with a 5-year CAGR of +19.1%.
Increased from $15M to $19M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +25.9%
- 5-Year CAGR
- +19.1%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 113This company $19.5M Sector average $11.3B
▼
-99.8% below sector average
Key checks
Key Insights
- IRADIMED CORP's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +19.1%, indicating consistent growth.
- In FY2025, cost of revenue increased 15.4% year-over-year.
- Ranks #110 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.29 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.5M | +15.4% |
| FY2024 | $16.9M | +9.7% |
| FY2023 | $15.4M | +57.8% |
| FY2022 | $9.8M | +10.8% |
| FY2021 | $8.8M | +8.3% |
| FY2020 | $8.1M | -7.6% |
| FY2019 | $8.8M | +43.2% |
| FY2018 | $6.2M | +5.4% |
| FY2017 | $5.8M | +71.6% |
| FY2016 | $3.4M | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026